LB Pharmaceuticals Inc LBRX R2KR3KPHARMA
Company Overview
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +185.20% |
| 6 Months: | +107.49% |
| 3 Months: | +72.94% |
| 1 Month: | +2.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LBRX LB Pharmaceuticals Inc R2KR3KPHARMA | 49.34 | -36.28 | $1.41B | 0.00% | -9.95% | -19.56% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Net Income | -16.22M | -27.63M | -14.18M | -5.31M | -4.87M | -3.56M | -19.05M |
| Diluted EPS | - | - | -39.49 | -14.79 | - | -0.61 | -0.67 |
| R&D Expense | - | - | 10.66M | 3.42M | - | 2.42M | 14.64M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.40M |
| Operating Income | -2.81M | -11.38M | -64.83M | -30.40M |
| EBITDA | -12.19M | -1.45M | -64.74M | -30.08M |
| Interest Expense | 2.15M | 4.83M | 0 | - |
| Pretax Income | -14.35M | -6.27M | -63.10M | -25.20M |
| Tax Provision | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -14.35M | -6.28M | -63.10M | -25.20M |
| Diluted EPS | -4.05 | -1.77 | -17.82 | -3.13 |
| R&D Expense | - | - | 51.17M | 16.74M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 33.53M | 312.93M |
| Total Equity | -34.47M | -94.55M | 301.31M |
| Cash & Equivalents | - | 22.98M | 250.17M |
| Total Liabilities | - | 13.83M | 11.62M |
| Current Liabilities | - | 8.11M | 7.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -53.05M | -35.21M |
| Investing Cash Flow | 23.23M | -39.89M |
| Financing Cash Flow | 38.31M | 302.56M |
| Capital Expenditure | -769.00K | -52.00K |
| Free Cash Flow | -53.82M | -35.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | - | 18.2% | 66.7% | -8.4% |
| ROCE % | - | - | -255.0% | -10.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, Lp | 10.39% | 3.35M | $160.03M |
| 2 | Blackrock Inc. | 8.48% | 2.73M | $130.51M |
| 3 | RA Capital Management, L.P. | 6.85% | 2.21M | $105.42M |
| 4 | Trails Edge Capital Partners, LP | 4.72% | 1.52M | $72.69M |
| 5 | Commodore Capital Lp | 4.65% | 1.50M | $71.59M |
| 6 | JPMORGAN CHASE & CO | 4.64% | 1.50M | $71.47M |
| 7 | TCG Crossover Management, LLC | 4.49% | 1.45M | $69.08M |
| 8 | Caligan Partners, LP | 4.46% | 1.44M | $68.64M |
| 9 | Spruce Street Capital LP | 4.27% | 1.38M | $65.68M |
| 10 | Nantahala Capital Management, LLC | 3.26% | 1.05M | $50.25M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LBRX
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.3% - Here's What Happened - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNZHpxZVoydzE5Zi1UZC1aNFZoUUlGYkFxTGFiOTZmUXdINlRFQmhNRXU0cHI2VmNNNWxXT2VuT1F4RTFxVzh1RDZPdnpjdWdrRlh2YTMzc1lnZW9IemFtNXFwSzhwWGl6dmp3R0Jqc1Z4QlpFWlFFY0RmU1BjbXM1NGo4dVpHWUtBWU9Lbm…
A finance executive who helped launch a lupus drug joins LB Pharmaceuticals - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNV0xacHRFR3dsa0JUTWViRXdBZFN0UVhmYXB0eGxxS0NxaGdxemdMNUdLUE56S2VadjF6N1QwV05GYWZrRE0tYlBKQWt6ZXVXY0tkdkpsanQ5SDgwa0U5Ni0xYkJrX05hNzkyWEJHTFdrNWMyOTRTYXp5b3ExMnl4ZFVjX2RiX0hoZkl5UF…
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNYzF0ZkpqbVBwZ3BCTWVqZUFPenpfZWRFOUtLYUZjSnpqWktMMUVkRmlQYXg4QzBzV0tETW9BQzVNWEw0dGh6WVU5QU1vYXlwMDBWTllBUkhURklFVktDMVJlZWxDTlF0VnNieWdzVzEtUWFSdEVqdV9TdDVjYVY0V2M1Y3lfU3RBNU5VSD…
LB Pharmaceuticals (NASDAQ: LBRX) Names Joseph M. Miller as CFO with $530K Salary and 200,000-Share Stock Option - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQQkw0UGk5T3UwT2oxdTFUSnhsSVBpYWIxTTlMbTJCNEhhelpTRjJEdkkxOGQ4VU1wbE0zN1lqQmYxbVJwbS1vRlFuUnE1eWJjcWd6XzhOM21MV2VXMFdxNFprZFdyR1Z2bWVQc3dqUlVGWXJiRDNDdFQ0VVczc1hqZHdHTlg3aHNXclkxNl…
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNbDdxWUlieHlkMDJhQzlsTlhneTNONkNGclp3TmFvcHJTNUxqVXFvMjJhYks0UHpmekNvazM1dlRhVlVLRXV4VjhaWjBxSkhENTFDOWYyYmdFUXhNaUxlNk41SFpnc3dUMjU4eGprN2tLQ2xpOGpRYzRtaTlmNTlONU9SWHpZV1AxT2dBNG…
LBRX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBPMlJOOVBUd01odHFKbUFGYWFUb1lpM0ZNQXk3Z2MzY2xrZFJ2eEZuZzY4OFpHMHdUNmZDbXlGLXhDRG5obFE?oc=5" target="_blank">LBRX</a> <font color="#6f6f6f">Finviz</font>…
LBRX — Frequently Asked Questions
What is the current share price of LB Pharmaceuticals Inc (LBRX)?
As of 2026-09-07 16:24 PDT, LB Pharmaceuticals Inc (LBRX) trades at $49.34 on NasdaqGM. Its 52-week range is $14.61 to $49.48.
What is the market capitalisation of LBRX?
LB Pharmaceuticals Inc (LBRX) has a market capitalisation of $1.41B on NasdaqGM.
What is the P/E ratio of LBRX?
LBRX trades at a trailing price-to-earnings (P/E) ratio of -36.28. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.63.
What is the return on equity (ROE) of LBRX?
LBRX has a return on equity (ROE) of -19.56%. Its return on capital employed (ROCE) is -9.95%.
Is LBRX a good stock to buy?
This page provides a data-driven analysis of LB Pharmaceuticals Inc (LBRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.